

ATTORNEY DOCKET NO. 09172.0006U1
Application Serial No. 10/625,645
SHEET 1 OF 1/8

## INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/625,645		
Filing Date	July 22, 2003		
First Named Inventor	Samual Christian		
Group Art Unit	1623		
Examiner Name	Leigh C. Maier		

Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if
LCM	A1*	3,929,813	December 30, 1975	Bodor	546	261	
БW	A2*	3,962,447	June 8, 1976	Bodor	424	263	
<b>~</b>	_A3_	5,380,837	January 10, 1995	Nakada et al	536	17.9.	
LCM	A4	5,639,737	June 17, 1997	Rubin	514	53	
LCM	A5*	6,339,064	January 15, 2002	McDevitt et al.	514	42	
LCM	A6	6,548,484	April 15, 2003	Christian	514	25	
LCM	A7	2006/0189547	August 24, 2006	Christian	514	23	
		·					
Examiner							

100	-*:		TENT DOCUMEN	TS	
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No
LCM	A8*	WO 97/28174	August 7, 1997	Oehrlein	
LCM	A9*	WO 01/97244	October 25, 2007	Christian	
	Signature:		Date Considere	ed:	<u> </u>
EXAMINE citation if not	R: Initial if re in conforman	eference considered, whether or ice and not considered. Include	not citation is in confor	mance with MPEP 609;	Draw line through

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(m)		NON-PATENT DOCUMENTS
Examin er's Initials	Cite No.	Non-Patent Citations (Include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
LCM	A10*	Alexander et al., "Role of conjugation and red blood cells for inactivation of ciculating catecholamines," Am. J. Physiol. 247(1):R203-R207 (1984)
LCM	A11*	Alvarado et al., "Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro," Biochim. Biophys. Acta 56:170-172 (1960)
LCM	A12*	Arita et al., "Studies on uptake of phenyl glycosides as inhibitors of D-glucose uptake by Rhesus monkey kidney cells," J. Biochem. 88:1399-1406 (1980)
LCW	A13*	Barnett et al., "Structural requirements for binding to the sugar transport system of the human erythrocyte," <i>Biochem. J.</i> 131:211-221 (1973)
LCM	A14*	Barnett et al., "Highlights of D1 dopamine receptor antagonist research," Neurochem. Int. 20 (Suppl.):119S-122S (1992)
LCM	A15*	Bencsics et al., "Dopamine, as well as, norepinephrine, is a link between noradrenergic nerve terminals and splenocytes," Brain Res. 761(2):236-243 (1997)

			•		•
Examiner Signature:				Date Considered:	9-24-07
<b>EXAMINER:</b> Initial if ref	erence c	onsidered	whether or no	citation is in conforman	e with MPED 600: Deputies they are
citation if not in conformance	e and ho	t consider	ed. Include cor	ov of this form with next of	communication to applicant.
647876					control to applicant.

DWP

# ATTORNEY DOCKET NO. 09172.0006U1 Application Serial No. 10/625,645 SHEET 2 OF X8

# INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary) Complete if Known Application Number 10/625,645 Filing Date July 22, 2003 First Named Inventor Samual Christian Group Art Unit 1623 Examiner Name Leigh C. Maier

	T	
	A16*	Berger et al., "Synthesis and receptor affinities of some conformationally restricted
LCM		analogues of the dopamine D1 selective ligand
J LL/M		(5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl- 1 H-3-benzazepin-7-ol," J. Med.
<b></b>	ļ	(1989)
LCM	A17*	Brewster et al., "trans-10,11-dihydroxy-5,6,7,8,12b-hexahydrobenzo[a]phen -anthridine: A
		highly potent selective dopamine D1 full agonist," J. Med. Chem. 33:1756-1764 (1990)
LCM	A18*	Bodor et al., "Elimination of a quaternary pyridinium salt delivered as its
LUM		dihydropyridine," J. Pharr. Sci, 67(5):685 (1978)
	A19*	Bodor, "Novel Approaches for the Design of Membrane Transport Properties of Drugs"
LCM		In: "Design of Biopharmaceutical Properties Through Prodrugs and Analogs", Ed. E.B.
Lu.	1	Roche et al. APhA Academy of Pharmaceutical Sciences, Washington, D.C., p. 98-
		135 (1976)
LCAA	A20*	Bodor et al., "Site-specific, sustained release of drugs to the brain," Science 214:1370-
LCM		1372 (1981)
1044	A21*	Bodor et al., "Redox delivery systems for brain-specific, sustained release of
LCM		dopamine," Science 221:65-67 (1983)
1.6.1	A22*	Casagrande et al., "Synthesis and chemical properties of lbopamine and of related
LCM		esters of N-substituted dopamines: Synthesis of Ibopamine metabolites,"
		Arzneim. Forsch. 36(2a):291-303 (1986)
	A23*	Chen et al., "Transport-dependent accessibility of a cytoplasmic loop cysteine in
LCM	1123	human denomina transporter" I Piel Cham 275(2) 1600 1614 (2000)
·	A24*	human dopamine transporter" J. Biol. Chem. 275(3):1608-1614 (2000)
LCM	724	Choi et al., "Novel 3-aminomethyland 4-aminopiperidine analogues of
um	1	1[2-(diphenylmethoxy)ethy1]-4-(3-phenylpropyl)piperazines: Synthesis and
	A25*	evaluation as dopamine transporter ligands," J. Med. Chem. 43(2):205-213 (2000)
LCM	AZS	Clarkson et al., "Immortalized dpamine neurons: A model to study neurotoxicity and
	A26*	neuroprotection," Proc. Soc. Exp. Biol. Med. 222(2):157-163 (1999)
	A20*	Claustre et al., "Conjugation and deamination of circulating dopamine: Relationship
LCM	j	between sulfated and free dopamine in man," J. Auton, Nerv. Syst. 29(2):175-182
	407+	(1990)
LCM	A27*	Coffey et al., "[3H]WIN 35,428 binding to the dopamine uptake carrier. I. Effect of
	4.20	tonicity and buffer composition," J. Neurosci. Methods 51(1):23-30 (1994)
LCM	A28	Czarnocki et al. "Enantiselective synthesis of (R)-(-)-Laudanosine and (R)-(-)-Glaucine
1.6.1	120+	from L-Ascorbic Acid," Tetrahedron: Assymetry, 7(9):2711-2720 (1996)
LCM	A29*	Dandrige et al. J. Med. Chem. 27:28 (1984)
LCM	A30*	Diez-Sampedro et al., "Galactose transport inhibition by cytochalasin E in rat
		intestine in vitro," Can. J. Physiol. Pharmacol. 77(2):96-101 (1999)
LCM	A31*	Duport et al., "An in vitro blood-brain barrier model: Cocultures between endothelial
الابلا		cells and organotypic brain slice cultures," Proc. Natl. Acad. Sci. USA 95(4):1840-
		[ 1845 (1998)
	A32*	Earles et al., "Multisubstrate mechanism for the inward transport of dopamine by the
LCM		numan dopamine transporter expressed in HEK cells and its inhibition by cocaine."
		Synapse 33(3):230-238 (1999)
	A33	Fernandez et al., "Synthesis and biological studies of glycosyl dopamine derivietives."
		Carbohyd. Res. 327:353-365 (2000)
LCM	A34*	Figlewicz, "Endocrine regulation of neurotransmitter transporters," Epilepsy Res. 37(3):
۱۰۱۰		203-210 (1999)

DUP

Examiner Signature: Luch C. Maur Date Considered: Q-24-07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#### **ATTORNEY DOCKET NO. 09172.0006U1** Application Serial No. 10/625,645 SHEET 3 OF X 8

#### **INFORMATION DISCLOSURE** STATEMENT LIST

(Use as many sheets as necessary)

_	Comple	ete if Known
	Application Number	10/625,645
	Filing Date	July 22, 2003
	First Named Inventor	Samual Christian
	Group Art Unit	1623
	Examiner Name	Leigh C. Maier

LCM	A35*	Findlay et al., "Inhibition of glycosidases by aldonolactones or corresponding configuration.  2. Inhibitors of b-N-acetylglucosaminidase," Biochemical J. 69:467-476 (1958)
LCM	A36*	Fischer et al., "5-Hydroxytraptamine stimulates glucose transport in cardiomyocytes via a monoamine oxidase-dependent reaction," <i>Biochem. J.</i> 311(2):575-583 (1995)
LCM	A37*	Fodor et al., Acta Chim. Acad. Sci. Hung. 28(4):409 (1961)
LCM	A38*	Freeman et al., "In: Chemical Regulation of Biological Mechanisms", Eds., Crieghton, A.M. and S. Turner. Royal Soc. Chemistry, London. pp 154-165 (1982)
LCM	A39*	Gainetdinov et al., "Functional hyperdopaminergia in dopamine transporter knock-out mice," Biol. Psychiatry 46(3):303-311 (1999)
LCM	A40*	Gee et al., "Quercetin glucosides interact with the intestinal glucose transporter pathway," Free Radic. Biol. Med. 25(1):19-25 (1998)
LCM	A41*	Gerding et al., "Metabolism and disposition of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5_hydroxytetraline in conscious monkeys after subsequent iv, oral and ocular administration," <i>Drug. Metab. Dispos.</i> 18(6):923-928 (1990)
LCM	A42*	Geurts et al., "Assessment of striatal D1 and D2 dopamine receptor-G protein coupling by agonist-induced [35S]GTP gamma S binding," Life Sci. 65(16):1633-1645 (1999)
LCM	A43*	Giros et al., "Cloning and functional characterization of a cocaine-sensitive dopamine transporter," FEBS Lett. 295:149-154 (1991)
LCM	A44*	Giros et al., "Cloning, pharmacological characterization and chromosome assignment of the human dopamine transporter," Mol. Pharmacol. 42(3):383-390 (1992)
LCM	A45	Glinsky et al. Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs Clin. Exp. Metastasis 14:253-267 (1996)
LCM	A46*	Green et al., "Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein," <i>Drug Metab. Dispos.</i> 24(3):356-363 (1996)
LCM	A47*	Haspel et al., "Effects of barbiturates on facilitative glucose transporters are pharmacologically specific and isoform selective," J. Membr. Biol. 169(1):45-53 (1999)
LCM	A48*	Hibert et al., "Graphics coputer-aided mapping as a predictive tool for drug design: Development of potent, selective and stereospecific ligands for the 5-HT1A receptor," J. Med. Chem. 31:1087-1093 (1988)
LCM	A49*	Horton, "Monosaccharide Amino Sugars. In: "The Amino Sugars": The Chemistry and Biology of Compounds Containing Amino Sugars. Vol. 1A. Ed. R.W. Jeanloz. Academic Press. N.Y. pp. 4-18 (1969)
LCM	A50*	Hurtig, "Problems with current treatment of Parkinson's disease," Exper. Neurol. 144:10-16 (1997)
LCM	A51*	Husbands et al., "Structure-activity relationships at the monoamine transporters as sigma receptors for a novel series of 9-[3-(cis,5-dimethyl-1-piperazinyl)propyl] carbazole (rmicazole) analogues," J. Med. Chem. 42 (21): 4446-4455 (1999)
LCM	A52*	Hyson et al., "Calcium channel blockers modify jejunal uptake of D-galactose in rabbits,"  Dig. Dis. Sci. 41(9):1871-1875 (1996)
LCM	A53*	Hyson et al., "A high cholesterol diet blocks the effect of calcium channel blockers on the uptake of sugars in rabbit intestine," Can. J. Physiol. Pharmacol. 75(1):57-64 (1997)
LCM	A54*	Iorio et al., "Benzazepines structure-activity relationships between D1 receptor blockade and selected pharmacological effects," In: Neurobiology of Central D1 Dopamine Receptors, Eds., G.R. Breese and I. Creese, Plenum Press, NY. pp. 1-14 (1986)
Examine	r Signatur	a: Aid ( Mains Date Omittee )

Examiner Signature: Date Considered: 9-24-07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#### **ATTORNEY DOCKET NO. 09172.0006U1** Application Serial No. 10/625,645 SHEET 4 OF X 8

#### **INFORMATION DISCLOSURE** STATEMENT LIST

(Use as many sheets as necessary)

THE WORK OF THE PERSON OF THE	<u> </u>
Comple	ete if Known
Application Number	10/625,645
Filing Date	July 22, 2003
First Named Inventor	Samual Christian
Group Art Unit	1623
Examiner Name	Leigh C. Maier

em.

	1	
LCM	A55*	Jaber et al., "Differential regulation of tyrosine hydroxylase in the basal ganglion of
	1.56	micre lacking the dopamine transporter," Eur. J. Neurosci. 11(10):3499-3511 (1999)
	A56	Jakas et al., "Syntheis and CNMR investigation of novel Amadori compounds (1-amino-
LCM		1-deoxy-D-fructose derivatives) related to the opioid peptide, leucine-enkephalin," J.
		Chem. Soc., Perkin Trans. 2:789-794 (1996)
LCM	A57	Jiang et al., "Dopaminergic properties and experimental anti-Parkinsonian effects,"
11/1		Clin. Neuropharmacol. 27(2):63-73 (2004)
LCM	A58*	Jones et al., "Dopamine neuronal transport kinetics and effects of amphetamine," J.
LLA		Neurochem. 73(6):2406-2414 (1999)
1 044	A59*	Jork et al., "The influence of dopamine on the incorporation of different sugars into total
LCM		proteins of hippocampal slices," Pharmacol. Biochem. Behav. 13(21):303-304 (1980)
LCM	A60*	Kaiser et al., J. Med. Chem. 25:697 (1982)
	A61*	Kawasaki et al., "The identification of two N-acyldopamine glucosides in the left
LCM		colleterial gland of the praying mantid, Tenodera aridifolia sinensis Saussure, and their
		role in the oothecal sclerotization insect," Biochem. 13:267-271 (1983) Insect Bioch
1.011	A62*	Kerwin et al., "Negative ion electrospray mass spectrometry of polyphenols,
LCM		catecholamines and their oxidation products," J. Mass Sprectrom. 31:1429-1439 (1996)
1 614	A63*	Kerwin, "Profiling peptide adducts of oxidized N-acetyldopamine by electrospray mass
LCM		spectrometry," Rapid Commun. Mass Sprectrom. 11:557-566 (1997)
	A64*	Kilbourn et al., "Rapid and differentiallosses of in vivo dopamine transporter (DAT) and
LCM	1	vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice,"
		Synapse 35(4):250-255 (2000)
LOM	A65*	Kitty et al., "Cloning and expression of a cocaine-sensitive rat dopamine transporter,"
13771		Science 254(5031):578-579 (1991)
	A66	Knoerzer et al., "Dopaminergic benzo[a]phenanthridines: Resolution and
	$\Gamma$	pharmacological evaluation of the enantiomers of dihydroxidine, the full efficacy D1
		dopamine receptor agonist," J. Med. Chem. 37:2453-2460 (1994)
LCM	A67*	Kuchel, "Peripheral dopamine in hypertension and associated conditions," J. Hum.
		Hypertens. 13(9):605-615 (1999)
LCM	A68*	Kuipers et al., 5-HT1A vs. D2-receptor selectivity of Flesinoxan and analogous N4-
//		substituted and N1-arylpiperazines," J. Med. Chem. 40:300-312 (1997)
LCM	A69*	Kumagai, "Glucose transport in brain and retina: Implications in the management and
LC/V[		complications of diabetes," Diabetes Metab. Res. Rev. 15(4):261-273 (1999)
LCM	A70*	Leal et al., "The metabolism of CGS15873 in man using stable isotope pattern
2400		recognition techniques," Biopharm. Drug Dispos. 13(8):617-628 (1992)
	A71*	Lichtenthaler, F.W. "Efficient Reaction Channels from Mono- and Disaccharides to
LCM		Enantiopure Building Blocks and Exploitation of Their Application Profiles" In:
		Carbohydrates: Synthetic Methods and Applications in Medicinal Chemistry, edited by
	1.55	Oqura, H., Hasegawa, A., and Suami, T.Tokyo:Kodansha, p. 3-27 (1992)
1.044	A72*	Liljefors et al., "A molecular mechanics approach to the understanding of
LCM		presynaptic selectivity for centrally acting dopamine receptor agonists of the
		phenylpiperidine series," J. Med. Chem. 29:1896 (1986)
LCM	A73	Likhoshersfov et al., "Sythesis of N-chloroacetyl-ß-glycopyranosylamines, deriviates
	A76	of monosaccharides and lactose," Russ. Chem. Bl. 45:1760-1763 (1996)
LCW	A74	Likhoshersfov et al., Russian Chemical Bulletin, 1998 47(6) page 1214-1217 (abstract)

Dup

Examiner Signature: Lugh C. Maur | Date Considered: 9-24-07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#### **ATTORNEY DOCKET NO. 09172.0006U1** Application Serial No. 10/625,645

#### SHEET 5 OF X 8

#### **INFORMATION DISCLOSURE** STATEMENT LIST

(Use as many sheets as necessary)

Comple	te if Known
Application Number	10/625,645
Filing Date	July 22, 2003
First Named Inventor	Samual Christian
Group Art Unit	1623
Examiner Name	Leigh C. Maier

Dus

DUP

LCM	A75*	Lostao et al., "Presence of leptin receptors in rat small intestine and leptin effect on sugar absorption," FEBS Lett. 423(3):302-306 (1998)
	A76*	Loland et al., "Defining proximity relationships in the tertiary structure of the dopamine
LCM		transporter. Identification of a conserved glutamic acid third coordinate in the
		endogenous Zn2+ binding site," J. Biol. Chem. 274:36928-36934 (1999)
ار ا	A77	Maher et al., "Substrate specifically and kinetic parameters of GLUT3," Biochem. J.
		315:827-831 (1996)
LCM	A78*	Manzi et al., "In: Glycobiology: A Practical Approach," Eds. M. Fukuda and A. Kobata.
12.700		IRL Press, Oxford University, Oxford. p. 29-31 (1993)
LCM	A79*	Martin et al., "Defects in Na+/glucose cotransporter (SGLT1) trafficking and function
LLM		cause glucose-galactose malabsorption," Nat. Genet. 12(2):216-220 (1996)
LCM	A80	Mathews et al. Biochemistry. Second Edition. The Benjamin/Cummings Publishing
14M		Company, Inc. p. 286 (1996)
LCM	A81*	Mattiuz et al., "Disposition and metabolism of olanzapine in mice, dogs and rhesus
		monkeys," Drug Metab. Dispos. 25(5):573-583 (1997)
LCM	A82*	McDermed et al., "Enantioselective binding of (+) and (-) 2-amiono-6,7-dihyroxy-
LLM		1,2,3,4-tetrahydronaphythalenes and related agonists to dopamine receptors." In:
		Catecholamines: Basic and Clinical Fronteins, Eds., E. Usdin, I.J. Kopin and J.
		Barchas, Pergamon Press, NY. p. 568-570 (1978)
ر ما	A83	Meiergerd et al., "Strietal transporter for dopamine," J. Neurochem. 62(3):998-1008
<u> </u>		(1994)
LCM	A84*	Melikian et al., "Membrane trafficking regulates the activity of the human dopamine
		transporter," J. Neurosci. 19(18):7699-7710 (1999)
LCM	A85	The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 13th Edition
LCIVI		447 1 (Maryadele J. O'Neil et al. Eds. 2001
LCM	A86*	Meyer et al., "Pharmacokinetics and first clinical experiences with an antihypertensive
	1054	dopamine (DA2) agonist," Eur. Heart J. 13(Suppl. D):121-128 (1992)
104	A87*	Mico et al., "Function-group metabolism of dopamine-2 agonists: Conversion of 4-(2-
LCM		di-N-propylamnoethyl)-2-(3H)-indolone to 4-(2-di-N-propylaminoethyl)-7-
	4.00#	hydroxyl-2-(3H)-indolone," J. Pharm. Sci. 75(10):929-933 (1986)
LCM	A88*	Miller et al., "Dopamine transporters and neuronal injury," Trends Phramacol. Sci.
	400#	20(10): 424-429 (1999)
LCM	A89*	Minor et al., "Synthesis and molecular modeling of 1-phenyl-1,2,3,4-
M/VL		tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-l3bH-dibenzo[a,h]quinolizines as
	400±	D1 dopamine antagonists," J. Med. Chem. 37:4317-4328 (1994)
LCM	A90*	Mizuma et al., "The beta-anomeric and glucose preferences of glucose transport carrier
144		for intestinal active absorption of monosaccharide conjugates," Biochim. Biophys. Acta
	A O 1	1200(2):117-122 (1994)
LCM	A91	Mizuma et al., "Intestinal active absorption of sugar-conjugated compounds by glucose
٠,,,		transport system: Implications for improvement of poorly absorbable drugs," Biochem.
	A92	Pharmacol. 43:2037-2039 (1992)
LCM	17.72	Mizuma et al., "Comparative study of active absorption by the intestine and disposition of
	A93*	anomers of sugar-conjugated compounds," Biochem. Pharmacol. 45(7):1520-1523 (1993)
LCM	A)	Morgan et al., "N-b-Alanylnorepinephrine: Biosynthesis in insect cuticle and possible role in sclerotization," Insect Biochem. 17: 255-263 (1987)
l		2 55-20 (198/)

Examiner Signature: Leigh (. Marer Date Considered: 9-24-07 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#### **ATTORNEY DOCKET NO. 09172.0006U1** Application Serial No. 10/625,645 SHEET 6 OF X8

#### **INFORMATION DISCLOSURE** STATEMENT LIST

(Use as many sheets as necessary)

	## ## ## ## ## ## ## ## ## ## ## ## ##
Complete if Known	
Application Number	10/625,645
Filing Date	July 22, 2003
First Named Inventor	Samual Christian
Group Art Unit	1623
Examiner Name	Leigh C. Maier

AND

	1 404#	16 1 160
LCM	A94*	Morgan et al., "Doparnine receptor subtypes and formalin test analgesia," <i>Pharmacol. Biochem. Behav.</i> 40(2):317-322 (1991)
LCM	A95*	Mueller et al., "1H and 13C NMR of 3-0 and 40 conjugates of dopamine and other catecholamines," <i>Bioconjug. Chem.</i> 4(1):47-53 (1993)
LCM	A96*	Navarro et al., "Effect of erythromycin on D-galactose absorption and sucrase activity in rabbit jejunum," Can. J. Physiol. Pharmacol. 71(3-4):191-194 (1993)
	A97	Ofinishi et al. J. Drug. Targeting (2000)
~	A98	Ovalle et al, "Systematic analysis of oxidative degradation" Carbohyd. Res. 330:131-139 (2000)
LCM	A99*	Petersson et al., "Conformational analysis and structure-activity relationships of selective dopamine D1 receptor agonists and antagonists of the benzazepine series," J. Med. Chem. 33:2197-2204 (1990)
LCM	A100*	Pokorski et al., "Fatty acid acylation of dopamine in the carotid body," Med. Hypothesis. 50(2):131-133 (1998)
LCM	A101*	Pocchiari et al., "Ibopamine, an orally active dopamine-like drug: Metabolism and pharmacokinetics in rats," ArzneimForsch. 36(2A):334-340 (1986)
LCM	A102*	Prakash et al., "Metabolism and excretion of a new anxiolytic drug candidate, CP-93,393, in healthy male volunteers," <i>Drug Metab. Dispos.</i> 26(5):448-456 (1998)
LCM	A103*	Prakash et al., "N-phenylalkyl-substitued tropane analogs of boat conformation of high selectivity for the dopamine versus serotonin transporter," <i>Bioorg. Med. Chem. Lett.</i> 9 (23):3325-3328 (1999)
LCM	A104*	Ramaswamy et al., "1-0-acyl derivatives of glucose as non-penetrating inhibitors of glucose transport by hamster small intestine in vitro," <i>Biochim. Biophys. Acta</i> 443:284-287 (1976)
LCM	A105*	Rhoads et al., "Circadian periodicity of intestinal Na+/glucose cotransporter 1 mRNA levels is transcriptionally regulated," J. Biol. Chem. 273(16):9510-9516 (1998)
LCM	A106*	Riggs et al., "Specific dopamine D-1 and DA1 properties of 4-(mono- and dihydroxyphenyl) -1,2,3,4-tetrahydroisoquinoline and its tetrahydrothieno [2,3-c] pyridine analogue," J. Med. Chem. 30:1454-1458 (1987)
LCM	A107	Roper et al., "NMR spectroscopy of N-(1-deoxy-D-fructos-1-YL)-L-amino acids ("fructose-amino acids)," Carb. Res. 116:183-195 (1983)
LCM	A108*	Schauer, "In: Methods in Enzymology," Ed. V. Ginsberg. Academic Press, NY. p. 64-89 (1978)
LCM	A109*	Seiler et al., "Further characterization of structural requirements for agonists at the striatal dopamine D-1 receptor. Studies with a series of monohydroxyaminotetralins on dopamine-sensitive adenylate cyclase and comparison with dopamine receptor binding," Mol. Pharmacol. 22:281-289 (1982)
LCM	A110*	Seiler et al., "Characterization of dopamine receptor subtypes by comparative structure-activity relationships: dopaminomimetic activities," J. Mol. Pharmacol. 35:643-651 (1989)
LCM	A111*	Seiler et al., "Trans-Hexahydroindolo[4,3-ab]phenanthridines ("Benzergolines"), the first structural class of potent and selective D1 receptor agonists lacking a catechol group," J. Med. Chem. 34(1):3113-3117 (1991) 303-307
LCW	A112*	Shimada et al., "Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 254(5031):576-578 (1991)

Examiner Signature: Lean C. Mary Date Considered: 9-24-07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# ATTORNEY DOCKET NO. 09172.0006U1 Application Serial No. 10/625,645 SHEET 7 OF X 8

### INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

	Complete if Known				
	Application Number	10/625,645			
	Filing Date	July 22, 2003			
	First Named Inventor	Samual Christian			
	Group Art Unit	1623			
į	Examiner Name	Leigh C. Maier			

	14.1.2.2	
	A113*	Shindo et al., "Metabolism of D- and L-isomers of 3,4 dihydroxyphenylalanine (DOPA).
Lem		V. Mechanism of intestinal absorption of carbon-14 labeled D- and L-doba in rats,"
		Chem. Pharm. Bull. 21(9):2031-2038 (1973)
	A114*	Shah et al., "(+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: Novel
LCM	1	dopamine D1 receptor antagonists," J. Med. Chem. 39:3423-3428 (1996)
	A115	Shukla et al., "Effect of desoxy-fructose derivatives of dopa and dopamine on body
LCM	11113	temperature " drahin fin draw sith survives (1), 102, 106 (1001)
<del></del>	A116#	temperature," Archiv für Arzneitherapie 5(1):183-195 (1981)
	A116*	Snyder et al., "Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro1H-
LCM		benzo[6,7]cycloheptal [1,2,3ef][3]benzazepine, 6,7-dihydroxy-2,3,4,8,9,12b-
	,	hexahydroanthra-[10,4a,4-c,d]azepine and 10-(aminomethyl)- 9,10-
į		dihydro-1,2-dihyroxyanthracene as conformationally restricuted analogs of b-
		phenyldopamine," J. Med. Chem. 38:2395-2409 (1995)
	A117*	Storch et al., "HEK-293 cells expressing the human dopamine transporter are
LCM		susceptible to low concentrations of 1-methyl-4-phenylpuridine acting via impairment
LUN		of energy metabolism." Naurochem Int. 25(5):202 402 (1000)
	A118*	of energy metabolism," Neurochem. Int. 35(5):393-403 (1999)
LCM	AIIo.	Sugamori et al., "A cognate dopamine transporter-like activity endogenously
	<del> </del>	expressed in a COS-7 kidney derived cell line," FEBS Lett. 451(2):169-174 (1999)
l	A119	Tamai et al., "Transporter-mediated permeation of drugs," J. Pharm. Sci. 89(11):1371-
		1388 (2000)
LCM	A120	Takata et al., "Transport of glucose across the blood-tissue barriers," Int. Rev.
١٨٨١	1	Cytology 172:1-53 (1997)
	A121	Tarjanyi et al. "Chromatographic investigation and computer simulation of (-)deprenyl
		metabolism," New Approaches Chromatog. 243-266 (1993)
LCM	A122*	Umegae et al., Anal. Chim. Acta 208:59 (1988)
12700		
LCM	A123*	van de Waterbeemd et al., "Quantitative structure-activity relationships and eudismic
LLM		analyses of the presynaptic dopaminergic," J. Med. Chem. 30:2175 (1987)
	A124*	Vandenbergh et al., "A human dopamine transporter cDNA predicts reduced
LCM		glycosylation, displays a novel repetitive element and provides racially-dimorphic Tagl
		RFLPs," Brain Res. Mol. Brain Res. 15(1-2):161-166 (1992)
	A125	Vannucci et al., "Glucose transporter expression in brain: Relationship to
LCM		cerebral glucose utilization," Dev. Neurosci. 20(4-5):369-379 (1998)
	A126* ·	Verhoeff et al., "Radiotracer imaging of dopaminergic transmission in
LCM		neuropsychiatric disorders," Psychopharmacol. (Berl) 147(3):217-249 (1999)
	A127*	Wang et al "Conjugation natterns of and annual laws and a law and
LCM	1.12/	Wang et al., "Conjugation patterns of endogenous plasma catecholamines in
	A120±	human and rat," J. Lab. Clin. Med. 101(1):141-151 (1983)
LCM	A128*	Wang et al., "Cathecholamine glucuronidation: An important metabolic pathway for
	1.405:	dopamine in the rat," J. Neurochem. 40(5):1435-1440 (1983)
LCM	A129*	Weinstock et al., Drugs Future 10:645 (1985)
1 CAA	A130*	Whitfield et al., "Acceleration of sugar transport in avian erythrocytes by
LCM		catecholamines," J. Biol. Chem. 249(13):4181-4188 (1974)
1.5.1	A131*	Wright et al., "Regulation of Na+/glucose cotransporters," J. Exp. Biol. 200(2):287-
LCM		293 (1997)
	A132*	
LCM	A132	Wu et al., "Molecular cloning of the mouse dopamine transporter and
		pharmacological comparison with the human homologue," Gene 233(1):163-170 (1999)
	L	(1777)

DUP

DUP

Examiner Signature: Luch C. Marcy | Date Considered: 9-24-07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#### ATTORNEY DOCKET NO. 09172.0006U1 Application Serial No. 10/625,645

SHEET 8 OF X S

#### **INFORMATION DISCLOSURE** STATEMENT LIST

(Use as many sheets as necessary)

	OTILET O OT IN D		
Complete if Known			
Application Number	10/625,645		
Filing Date	July 22, 2003		
First Named Inventor	Samual Christian		
Group Art Unit	1623		
Examiner Name	Leigh C. Maier		

D	up
-	•

A133 Wunder et al., "Enhanced albumin uptake by rat tumors," Int. J. Oncol. 11:497-507 (1997)		
Examiner Signature: Leigh C. Maur	Date Considered: 9-24-07	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and net considered. Include copy of this form with next communication to applicant.		